Opendata, web and dolomites

Lymphit

LYMPHIT: an innovative easy-to-use and cost-efficient diagnostic microneedle patch for the early detection of Lymphedema

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Lymphit project word cloud

Explore the words cloud of the Lymphit project. It provides you a very rough idea of what is the project "Lymphit" about.

additional    lymphedema    first    conservative    worsening    quantitatively    scalable    productivity    life    global    25    boost    company    contain    healthcare    extremely    medical    earliest    physical    chronic    tracking    care    lymphatic    diagnostic    fold    patients    profile    quality    approved    fifth    microneedles    empowering    optimization    patches    64    disease    revenues    decay    fluorescent    icg    clinicians    practitioners    painless    status    limb    validation    instrument    detect    debilitation    minimally    detection    disrupting    clinical    dissolving    accumulation    treatments    inadequate    roi    complications    worldwide    progressive    function    agent    secondary    generating    commercialized    fluorescence    patient    lymphit    oncologic    selectively    optically    market    complete    occurring    outlined    swelling    fluids    psychological    diagnosis    sme    398m    ftes    acute    stage    polymeric    completion    fda    tool    social    markets    reduce    50    manner    dicronis    invasive    serious    prescribe    safety    decreasing    later   

Project "Lymphit" data sheet

The following table provides information about the project.

Coordinator
DICRONIS SAGL 

Organization address
address: VIA CAMPAGNA 57
city: MONTEGGIO
postcode: 6998
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.dicronis.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DICRONIS SAGL CH (MONTEGGIO) coordinator 50˙000.00

Map

 Project objective

Lymphedema is a chronic condition, outlined by a progressive accumulation of fluids in a limb, leading to great physical and psychological debilitation of the affected patient and often occurring secondary to oncologic treatments. There is not early diagnosis for lymphedema. Current diagnostic methods are highly inadequate and detect the disease only at an advanced stage, leading to serious complications, greatly decreasing quality-of-life of the patients while increasing healthcare costs. In response to this challenge, Dicronis has developed a diagnostic tool (LYMPHIT) based on a painless and minimally-invasive delivery of ICG, an FDA approved fluorescent agent, with an extremely high safety profile, integrated into polymeric dissolving microneedles patches which allows determining the status of the lymphatic system by optically measurement of the fluorescence decay. LYMPHIT enables patients and clinicians the earliest possible detection of lymphedema, by quantitatively tracking the function of the lymphatic system in a painless, easy-to-use and highly-scalable manner. LYMPHIT will be disrupting in the market by empowering medical practitioners to timely and selectively prescribe conservative treatments, which can contain or avoid a worsening of the swelling in the affected limb. Therefore, LYMPHIT will reduce lymphedema treatments costs up to 50% and reduce 10-fold the social costs associated to productivity loss, both of them associated with late stage lymphedema. Upon completion of the project, LYMPHIT will boost the growth of our company generating additional 64 FTEs, revenues of €398M and a ROI of 10.25 by the fifth year after Phase 2 execution. With the help of the SME instrument, Dicronis aims to complete the product optimization and clinical validation so that it can be commercialized across European markets first, and global markets later on, improving the quality of care of healthcare systems worldwide as well as the lymphedema patient´s quality of life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LYMPHIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LYMPHIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More